Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine-Reference-Cited by-同舟云学术

Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine

Published:2020-04-11 Issue:5 Volume:85 Page:941-947
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Soyama Hiroaki^ORCID,Miyamoto Morikazu^ORCID,Matsuura Hiroko,Iwahashi Hideki^ORCID,Kakimoto Soichiro^ORCID,Ishibashi Hiroki^ORCID,Sakamoto Takahiro^ORCID,Hada Taira^ORCID,Suminokura Jin,Takano Masashi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-020-04070-8.pdf

Reference24 articles.

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551

2. Lheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet 393:1240–1253. https://doi.org/10.1016/S0140-6736(18)32552-2

3. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308. https://doi.org/10.1200/JCO.2013.51.4489

4. Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in Platinum-Resistant Recurrent Ovarian Cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 33:3836–3838. https://doi.org/10.1200/JCO.2015.63.1408

5. Takasaki K, Miyamoto M, Takano M, Soyama H, Aoyama T, Matsuura H, Kato K, Sakamoto T, Kuwahara M, Iwahashi H, Ishibashi H, Yoshikawa T, Furuya K (2018) Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer Chemother Pharmacol 81:809–814. https://doi.org/10.1007/s00280-018-3552-5

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma;Cancer Immunology Research;2023-06-06

2. Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease;eBioMedicine;2023-06

3. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study;Acta Neuropathologica Communications;2022-01-03

4. Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer;International Journal of Molecular Sciences;2021-12-20

5. Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management;Seminars in Cancer Biology;2021-12